rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IDYA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?

      IDEAYA Biosciences (IDYA) is back in focus after outlining an FDA backed registrational plan for IDE849, its DLL3 targeted antibody drug conjugate in difficult neuroendocrine and small cell lung cancers. Against this clinical backdrop, IDEAYA Biosciences has seen momentum cool, with the share price down 9.72% over the past day and 16.56% over 30 days, contributing to a 29.48% decline over 90 days and a 19.03% year to date share price fall. However, the 5 year total shareholder return of...

      Nov 18Yahoo FinanceIDYA
      Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More

      Ideaya Biosciences is continuing to advance its first-in-class, oral, small-molecule protein kinase C [PKC] inhibitor darovasertib. I rate IDYA stock as Strong Buy.

      Nov 17Seeking AlphaIDYA
      IDEAYA Biosciences at Jefferies: darovasertib nears approval
      Nov 17Investing.comIDYAJEF
      Ideaya picks cancer drug candidate, targets human trial application in 2027 (IDYA:NASDAQ)
      Nov 16Seeking AlphaIDYA
      Mizuho cuts Ideaya Biosciences stock price target on dilution
      Nov 9Investing.comIDYA
      IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
      Nov 4MorningstarIDYA
      Truist cuts Ideaya Biosciences stock price target on revised estimates
      Nov 3Investing.comIDYA
      IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
      Nov 3Yahoo FinanceIDYA
      Ideaya Biosciences earnings missed by $0.05, revenue topped estimates
      Nov 3Investing.comIDYA
      IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
      Nov 3MorningstarIDYA
      Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
      Oct 31Yahoo FinanceIDYA
      IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
      Oct 27Yahoo FinanceIDYA
      Citizens reiterates Ideaya Biosciences stock rating on darovasertib data
      Oct 27Investing.comIDYA
      IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors
      Oct 23Investing.comIDYA
      IDEAYA presents uveal melanoma trial data at ESMO 2026
      Oct 19Investing.comIDYA
      Citizens reiterates Ideaya Biosciences stock rating ahead of ESMO
      Oct 19Investing.comIDYA
      William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating
      Oct 16Yahoo FinanceIDYA
      William Blair initiates Ideaya Biosciences stock with outperform rating
      Oct 16Investing.comIDYA
      IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma (IDYA:NASDAQ)

      Stifel restarts IDEAYA coverage: darovasertib + crizotinib may become uveal melanoma standard of care. Read more here.

      Oct 14Seeking AlphaIDYASF
      Stifel initiates Ideaya Biosciences stock with buy rating
      Oct 13Investing.comIDYA
      IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
      Oct 8Yahoo FinanceIDYA
      Idea Biosciences president and CEO Yujiro Hata sells $985k in shares
      Oct 8Investing.comIDYA
      Cantor Fitzgerald reiterates Ideaya Biosciences stock rating
      Oct 6Investing.comIDYA
      IDEAYA Biosciences promotes Michael White to R&D president
      Sep 28Investing.comIDYA
      IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
      Sep 28Yahoo FinanceIDYA
      Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

      Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]

      Sep 25Yahoo FinanceIDYA
      IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      --IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three...

      Sep 25NasdaqIDYA
      Cantor Fitzgerald reiterates Ideaya Biosciences stock rating
      Sep 22Investing.comIDYA
      IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push
      Sep 14Investing.comIDYAMS
      IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth
      Sep 10Investing.comIDYAC
      Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

      Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailGLUEIDYA
      IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push
      Sep 9Investing.comIDYA
      Guggenheim raises Ideaya Biosciences stock price target on DLL3 data
      Sep 9Investing.comIDYA
      IDEAYA at wells fargo healthcare conference: darovasertib nears NDA
      Sep 8Investing.comIDYAWFC
      Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

      Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailIDYAVOR
      IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
      Sep 1MorningstarIDYA
      Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress
      Sep 1Investing.comIDYA
      IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

      IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year

      Aug 31Yahoo FinanceIDYA
      IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy

      IDEAYA Biosciences (IDYA) said Monday it held a US Food and Drug Administration meeting on the desig

      Aug 31Yahoo FinanceIDYA
      IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
      Aug 28MorningstarIDYA
      Ideaya Biosciences stock hits 52-week high at 40.88 USD
      Aug 25Investing.comIDYA
      Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA)
      Aug 25Seeking AlphaIDYA

      This is the newest page. Registered accounts read further back.